30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: Stryker

$2,363MM, +7% (U.S. $1,569MM, +8%; ex-U.S. $794MM, +5%)

Reconstructive $1,028MM, +6% (excluding acquisition, +4%) (U.S. +11%, ex-U.S. +0.2%)

  • Hips $326MM, +2% (U.S. +6%, ex-U.S. -3%)
  • Knees $350MM, +3% (U.S. +7%, ex-U.S. -6%)
  • Trauma/Extremities $298MM, +11% (U.S. +13%, ex-U.S. +9%)

 

*MedSurg $905MM, +9%

  • Endoscopy $336MM, +18% (U.S. +17%, ex-U.S. +20%)

 

Neurotechnology/Spine $430MM, +4% (U.S. +1%, ex-U.S. +9%)

  • Neurotechnology $245MM, +8% (U.S. +8%, ex-U.S. +8%)
  • Spine $185MM, -2% (U.S. -6%, ex-U.S. +10%)

 

*MedSurg includes patient handling and emergency medical equipment.

 

  • Ex-U.S. growth led by strong double-digits in Brazil, China, India; partially offset by market conditions in Russia
  • Recon pricing -2.9%
  • Foot/ankle +30%
  • U.S. spine sales reflect impact of price pressure, some salesforce disruption
  • Commenced limited launch of reverse shoulder via hybrid recon salesforce, full launch by end of 3Q
  • ~20% of 1,000 U.S. MAKO reps trained
  • Planning 2015 launch of Total Knee and key hip systems on MAKO
  • Closed Berchtold acquisition, generated >100 new leads
  • Pivot Medical revenue (from 350+ customers) reporting within sports medicine unit of Endoscopy
  • Positive early response to CoAlign spinal product acquisition
  • Planning 2015 launch of Trauson products to India

 

Announced acquisition of Small Bone Innovations (SBi):

  • Meaningful supplement to small bone fixation portfolio
  • Minimal overlap with existing products
  • STAR total ankle represented ~50% of SBi sales
  • ~50% of SBi surgeons not currently customers of Stryker products